
Perivinc Pharmaceuticals Private Limited
About Perivinc Pharmaceuticals Private Limited
Data last updated:
Perivinc Pharmaceuticals Private Limited is a private limited company based in Tal Viramgam, Gujarat, India, a subsidiary of Yashica Pharmaceuticals Private Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 19 August 2010 and has been in existence for over 16 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24230GJ2010PTC062038. Its GSTIN is 24AAFCP6352G1ZH (Gujarat).
The company has an authorised share capital of ₹4 Cr and a paid-up capital of ₹3.94 Cr. It is led by directors including Sanjay Patel and Sanjay Khandu Totare.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Plot No. 257 GIDC Viramgam (Hansalpur), Tal Viramgam, Gujarat, India – 382150.
As per the financials filed for FY 2025, the company reported a revenue of ₹4.83 Cr, a growth of 23% compared to the previous year. For the same year it recorded a net loss of ₹2.66 Lakh (net margin -0.6%) and EBITDA of ₹87.45 Lakh (EBITDA margin 18.1%). Revenue has grown at a compounded annual rate (CAGR) of 38% over three years and 18% over five years.
As per MCA filings, the company has open charges of ₹2 Cr and satisfied charges of ₹7 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Perivinc Pharmaceuticals Private Limited's registered office is in Tal Viramgam, Gujarat. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressPlot No. 257 GIDC Viramgam (Hansalpur), Tal Viramgam, Gujarat, India – 382150
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Perivinc Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Perivinc Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Perivinc Pharmaceuticals Private Limited, buy the company report.
Financials of Perivinc Pharmaceuticals Private Limited
FY 2024 filings availablePerivinc Pharmaceuticals Private Limited reported revenue of ₹4.83 Cr (up 23% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 18% over five years, including 23% growth in the latest year. EBITDA rose 24% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹87.45 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹2.66 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 18.1% | ||||
| Net Profit Margin | -0.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Perivinc Pharmaceuticals Private Limited, buy the company report.
Board of directors of Perivinc Pharmaceuticals Private Limited
Perivinc Pharmaceuticals has 4 current directors and 11 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sanjay Patel | Director | 16 Apr 2019 | 7 Years 7 Months | Current |
| Sanjay Khandu Totare Also directs: Yashica Pharmaceuticals Private Limited | Director | 06 Mar 2018 | 8 Years 8 Months | Current |
| Vaishali Sanjay Totare Also directs: Yashica Pharmaceuticals Private Limited | Director | 06 Mar 2018 | 8 Years 8 Months | Current |
| Patel Anilkumar Sankabhai Also directs: Aniket Pharma Private Limited, Kenil Healthcare Private Limited | Director | 16 Apr 2019 | 7 Years 7 Months | Current |
Auditor
Perivinc Pharmaceuticals Private Limited is audited by MADAN ACHWAL & CO for the financial year 2021.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MADAN ACHWAL & CO | FY 2021 | 105693W |
Shareholding
The shareholding of Perivinc Pharmaceuticals Private Limited is on record for 4 financial years, the latest being FY 2021, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2021 | FY 2020 | FY 2017 | FY 2016 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Perivinc Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 01 Feb 2023 | 100688899 | Axis Bank Limited | ₹2 Cr | Open | |
| 18 May 2013 | 10432806 | Bank of India | ₹3.5 Cr | Satisfied | |
| 11 May 2013 | 10432803 | Bank of India | ₹3.5 Cr | Satisfied |
To see the full charge records of Perivinc Pharmaceuticals Private Limited, buy the company report.
Total charge records: 3 View all charges
Legal cases
No court or tribunal cases involving Perivinc Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Perivinc Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Perivinc Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAFCP6352G1ZH | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Perivinc Pharmaceuticals Private Limited, buy the company report.
Recent activity
Perivinc Pharmaceuticals Private Limited has 15 board changes on record since 2018: 4 appointments and 11 cessations. The latest: Patel Anilkumar Sankabhai ceased to be Additional Director on 30 Sep 2019.
11 earlier events are in the company report.
Frequently asked questions
Perivinc Pharmaceuticals is an active private limited company based in Tal Viramgam, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 19 August 2010 (16+ years old) and is registered under CIN U24230GJ2010PTC062038.
Perivinc Pharmaceuticals has 4 current directors:
- Sanjay Patel - Director
- Sanjay Khandu Totare - Director
- Vaishali Sanjay Totare - Director
- Patel Anilkumar Sankabhai - Director
The latest financial statements of Perivinc Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Perivinc Pharmaceuticals is 24AAFCP6352G1ZH, registered in Gujarat.
The CIN (Corporate Identification Number) of Perivinc Pharmaceuticals is U24230GJ2010PTC062038. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Perivinc Pharmaceuticals was incorporated on 19 August 2010, making it 16+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Patel Anilkumar Sankabhai ceased to be Additional Director on 30 Sep 2019. Sanjay Patel ceased to be Additional Director on 30 Sep 2019. Patel Anilkumar Sankabhai was appointed as Director on 16 Apr 2019. Perivinc Pharmaceuticals has 15 board changes on record in total.
The registered office of Perivinc Pharmaceuticals is at Plot No. 257 GIDC Viramgam Hansalpur, Tal Viramgam, Gujarat, India – 382150.
Perivinc Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.
Perivinc Pharmaceuticals has open charges of ₹2 Cr and satisfied charges of ₹7 Cr as per latest MCA filings.

